News and Trends 24 Oct 2019
German Alzheimer’s Drug Backed with €43M After Biogen’s Surprise Turnaround
The German company Vivoryon Therapeutics has raised €43M on Euronext Amsterdam to fund a phase IIb trial of a drug that could slow the progression of Alzheimer’s disease by blocking…